Skd pomys, by pielgnacj wosw dostosowa do pr roku
Window: 12 to 18 months before academic consensus closes the first-mover advantage
People who are very lean in the abdominal area, particularly men with low body fat percentages, may find this site less comfortable and should consider the thigh as their primary site instead
References SURMOUNT-5 head-to-head trial (NEJM, May 2025) summary via American College of Cardiology: SURPASS-2 primary publication (NEJM, 2021): Eli Lilly SURMOUNT-1 results announcement (NEJM data): Insights into the Mechanism of Action of Tirzepatide (PMC narrative review): Tirzepatide is an imbalanced and biased dual GIP/GLP-1 receptor agonist (PMC): SURMOUNT-5 GI tolerability / discontinuation data (Applied Clinical Trials, tctmd, DiabetesontheNet coverage): SURMOUNT-1 to -4 GI tolerability (Rubino 2025, Diabetes Obesity & Metabolism): Community sentiment context Reddit GLP-1 side-effect analysis and comparative meta-analyses (PMC): Research Use Only Notice: The content on this page is provided for informational and educational purposes only
Attach Needle: Remove the paper tab, twist on the needle, and remove both caps
Neurotherapeutics 18 (2), 962978
